Physician profile
Paul Keck
NPI 1710062872
$738,524.10
in general payments reported to CMS, 2019-2025
13 companies · $182K in 2025
The $182K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $61K · 2021: $25K · 2022: $163K · 2023: $171K · 2024: $112K · 2025: $182K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $231K · Consulting Fee: $150K · Honoraria: $52K · Travel and Lodging: $20K · Food and Beverage: $7,368 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,844.29 |
| Consulting Fee | $150,399.00 |
| Honoraria | $51,640.00 |
| Travel and Lodging | $19,699.54 |
| Food and Beverage | $7,367.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $186,708.80 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $114,198.66 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $112,330.30 | 2020-2025 | Lybalvi, Aristada |
| Abbvie INC. | $105,356.28 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77,706.73 | 2025 | Caplyta |
| Allergan, INC. | $75,327.15 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $27,944.64 | 2020-2023 | Abilify Maintena, Abilify Asimtufii |
| Eli Lilly and Company | $11,584.91 | 2025 | |
| Merck Sharp & Dohme LLC | $10,783.44 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $8,568.57 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $3,565.62 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $2,525.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,924.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Keck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.